In a press release it has been announced that the European Commission has concluded its look into Europe’s pharmaceutical industry and has decided to take action against pharmaceutical companies in three major cases, issuing the companies statements of objections. The inquiry into the sector ran from 2008-2009. In its search, the Commission found weaker-than-expected competition contributed by generic producers, attributing the find to pay-for-delay transactions, as well as competition problems by market dominators who look to shut out the generic competitors from the market. Following these findings, the Commission sent statements of objections to more than 14 companies in two cases of possible competition infringement through “anticompetitive agreements and, in part, unilateral practices.”
Full Content: European Commission
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI